Bain Capital Life Sciences Investors as of Sept. 30, 2024
Portfolio Holdings for Bain Capital Life Sciences Investors
Bain Capital Life Sciences Investors holds 24 positions in its portfolio as reported in the September 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Nuvalent Inc-a (NUVL) | 28.7 | $276M | 2.7M | 102.30 | |
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 18.1 | $174M | 11M | 16.60 | |
| Disc Medicine (IRON) | 9.2 | $88M | 1.8M | 49.14 | |
| Dianthus Therapeutics (DNTH) | 8.6 | $83M | 3.0M | 27.38 | |
| Savara (SVRA) | 6.4 | $62M | 15M | 4.24 | |
| Pharvaris N V (PHVS) | 6.4 | $61M | 3.3M | 18.52 | |
| Annexon (ANNX) | 5.2 | $50M | 8.4M | 5.92 | |
| Solid Biosciences Com New (SLDB) | 2.9 | $28M | 4.0M | 6.97 | |
| Tango Therapeutics (TNGX) | 2.2 | $21M | 2.7M | 7.70 | |
| Kyverna Therapeutics (KYTX) | 1.7 | $17M | 3.4M | 4.89 | |
| Mersana Therapeutics | 1.7 | $16M | 8.7M | 1.89 | |
| Cabaletta Bio (CABA) | 1.4 | $13M | 2.8M | 4.72 | |
| X4 Pharmaceuticals | 1.2 | $11M | 17M | 0.67 | |
| Century Therapeutics (IPSC) | 1.0 | $9.3M | 5.4M | 1.71 | |
| Atea Pharmaceuticals (AVIR) | 0.9 | $8.3M | 2.5M | 3.35 | |
| Cidara Therapeutics Com New (CDTX) | 0.8 | $7.6M | 703k | 10.75 | |
| Rapid Micro Biosystems Class A Com (RPID) | 0.8 | $7.5M | 8.4M | 0.89 | |
| C4 Therapeutics Com Stk (CCCC) | 0.7 | $6.3M | 1.1M | 5.70 | |
| Syros Pharmaceuticals Com New (SYRS) | 0.6 | $5.9M | 2.8M | 2.15 | |
| Nautilus Biotechnology (NAUT) | 0.6 | $5.7M | 2.0M | 2.85 | |
| Marinus Pharmaceuticals Com New | 0.5 | $4.7M | 2.7M | 1.76 | |
| Xilio Therapeutics (XLO) | 0.4 | $3.6M | 4.6M | 0.79 | |
| Adagio Therapeutics (IVVD) | 0.2 | $1.8M | 1.8M | 1.02 | |
| Newamsterdam Pharma Company *w Exp 99/99/999 (NAMSW) | 0.1 | $700k | 100k | 7.00 |
